First vaccinations in Phase I clinical trial of Lassa fever vaccine candidate - IAVI. IAVI announces first vaccinations in Liberia Phase I clinical trial of Las
A novel vaccine candidate against Lassa fever virus (LASV) has successfully launched a Phase I clinical trial supported by the Coalition for Epidemic Preparedness Innovations (CEPI). CEPI's ultimate goal, as part of its plan to minimize or even eliminate the risk of future epidemic and pandemic threats, is to produce a licensed Lassa vaccine for routine immunization. Although several LASV vaccine candidates are conducting studies, the U.S. FDA has not approved one as of August 31, 2022.
IAVI Announces First Vaccinations at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate - read this article along with other careers information, tips and advice on BioSpace
Why efforts to make better, more universal coronavirus vaccines are struggling science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.